Infliximab maintenance dosing in inflammatory bowel disease: an example for in silico assessment of adaptive dosing strategies

Background: Infliximab is an anti-tumour necrosis factor alpha monoclonal antibody used to treat inflammatory bowel diseases.  Unfortunately, not all patients demonstrate an initial response during induction, whilst others respond initially but relapse within one year of treatment.  Adapting doses based on clinical outcomes and trough concentrations can improve response and reduce the proportion that develop antibodies […]

A Systematic Evaluation of Single Metrics in Discriminating Changes in Rheumatoid Arthritis Disease Activity

Background: The treat-to-target approach in the management of rheumatoid arthritis involves frequent assessments of a patient’s disease activity to guide drug dose and regimen adjustments until a pre-defined low disease activity state and/or remission has been achieved. However, which metric (single or a composite) that best reflects response to therapy and a change in disease […]